Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
Randomized Clinical Study for Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax, Marketed by the Blausiegel Laboratory, Compared to Drug Eprex, Produced by Janssen-Cilag Laboratory, in Healthy Subjects.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
São Paulo
-
Valinhos, São Paulo, Brazil, 13270000
- LAL Clínica Pesquisa e Desenvolvimento Ltda.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirm the voluntary participation and agree to all the purposes of the study by signing and dating the IC in two ways;
- Being male, aged between 20 and 55 years, clinically healthy;
- BMI between 18 and 25;
- Results of examination of hemoglobin between 13.8 and 15.4 g / dL and hematocrit between 41% and 49%;
- Results of VCM, HBMC, platelets and leukocytes within the normal range:
VCM = Between 82 to 98. Among the HBMC = 26 to 34. Among the platelets = 150,000 to 400,000 units per mL. Among the WBC = 3,500 to 10,500 units per mL and without cellular atypia.
- Serum ferritin = Male between 36 to 262 mcg / L and women between 24 to 155 mcg / L;
- Reticulocyte count in peripheral blood ≤ 3%;
- Serum erythropoietin less than 30 mIU / mL.
Exclusion Criteria:
- Participation in clinical trials in the 12 months preceding the survey;
- Presence of iron deficiency anemia;
- Presence of pulmonary diseases, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems;
- Acute disease in the period of 07 days prior to inclusion;
- Chronic administration of medication to determine, such as high blood pressure;
- Hormone therapy in the period of 02 months prior to inclusion;
- Administration of any drug in the 02 weeks prior to inclusion;
- A history of autoimmune anemia or hereditary;
- research subjects with a history of chronic bleeding;
- research subjects with a history of acute bleeding in the last 30 days;
- History of sensitivity to biological products derived from mammals, albumin, or any component of the formulation;
- History of or current use at least 12 months of tobacco;
- Current or previous history (less than 12 months) of illicit drug use;
- previous therapy with erythropoietin;
- albumin below 3.5 g / dl or greater than 4.8 g / dL;
- Signs or clinical history of bone marrow aplasia;
- History of liver disease and clinical or laboratory;
- History of renal disease and clinical or laboratory.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Test ERITROMAX
Blausiegel Industria e Comercio Ltda.
Recombinant Human Erythropoietin (ERITROMAX)
|
The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
Other Names:
|
|
ACTIVE_COMPARATOR: EPREX
Janssen-Cilag Recombinant Human Erythropoietin (EPREX)
|
The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetic - rHuEPO concentration.
Time Frame: Before administration (Time 0 hour) and after time 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 11 hours, 12 hours, 13 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours and 120 hours administration.
|
Will evaluated through the plasma rHuEPO dosage before and after drug administration.
|
Before administration (Time 0 hour) and after time 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 11 hours, 12 hours, 13 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours and 120 hours administration.
|
|
Pharmacodynamics - Absolute Reticulocyte Count.
Time Frame: Before administration (Time 0 hour) and after Time 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, 240 hours and 576 hours administration.
|
Will evaluated through the absolute reticulocyte count at total blood.
|
Before administration (Time 0 hour) and after Time 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, 240 hours and 576 hours administration.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Alexandre Frederico, PI, LAL Clínica Pesquisa e Desenvolvimento Ltda
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EPOBLA0711I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.